Endocrine complications of immunotherapies : a review
© Royal College of Physicians 2021. All rights reserved..
Use of immune checkpoint inhibitors in cancer treatment has increased vastly over the past decade, as both single and combination agent therapies. While having a positive impact on survival rates, adverse effects have been noted, with endocrine effects in around 10% of patients. Thyroid disease and hypophysitis are the most commonly encountered, with diabetes mellitus and primary adrenal insufficiency also reported, as well as more rare endocrinopathies. Patient and clinician education to raise awareness of these effects, as well as regular monitoring to enable early recognition, diagnosis and prompt treatment of the immune side effects, are key. In this review, we discuss the aetiology, presentation and management of the endocrine complications of immunotherapies that are relevant to the general physician, as well as highlighting important areas where further research is still needed.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Clinical medicine (London, England) - 21(2021), 2 vom: 07. März, Seite e212-e222 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hattersley, Rosie [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cancer |
|---|
| Anmerkungen: |
Date Completed 20.05.2021 Date Revised 26.04.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.7861/clinmed.2020-0827 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM323184057 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM323184057 | ||
| 003 | DE-627 | ||
| 005 | 20240426232914.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.7861/clinmed.2020-0827 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1388.xml |
| 035 | |a (DE-627)NLM323184057 | ||
| 035 | |a (NLM)33762389 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hattersley, Rosie |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Endocrine complications of immunotherapies |b a review |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.05.2021 | ||
| 500 | |a Date Revised 26.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Royal College of Physicians 2021. All rights reserved. | ||
| 520 | |a Use of immune checkpoint inhibitors in cancer treatment has increased vastly over the past decade, as both single and combination agent therapies. While having a positive impact on survival rates, adverse effects have been noted, with endocrine effects in around 10% of patients. Thyroid disease and hypophysitis are the most commonly encountered, with diabetes mellitus and primary adrenal insufficiency also reported, as well as more rare endocrinopathies. Patient and clinician education to raise awareness of these effects, as well as regular monitoring to enable early recognition, diagnosis and prompt treatment of the immune side effects, are key. In this review, we discuss the aetiology, presentation and management of the endocrine complications of immunotherapies that are relevant to the general physician, as well as highlighting important areas where further research is still needed | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a cancer | |
| 650 | 4 | |a endocrine | |
| 650 | 4 | |a hypophysitis | |
| 650 | 4 | |a immunotherapy | |
| 650 | 4 | |a thyroid | |
| 700 | 1 | |a Nana, Melanie |e verfasserin |4 aut | |
| 700 | 1 | |a Lansdown, Andrew J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical medicine (London, England) |d 2001 |g 21(2021), 2 vom: 07. März, Seite e212-e222 |w (DE-627)NLM112411673 |x 1473-4893 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2021 |g number:2 |g day:07 |g month:03 |g pages:e212-e222 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.7861/clinmed.2020-0827 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2021 |e 2 |b 07 |c 03 |h e212-e222 | ||